Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

42 results
Display

Result Patterns and Characteristics of HBeAg and HBV DNA in Patients with Chronic Hepatitis B

Choi EJ, Kim JH, Han MS

BACKGROUND: Discrepancies in the results between hepatitis B e-antigen (HBeAg) and hepatitis B virus (HBV) DNA levels pose difficulties in the management of chronic hepatitis B (CHB). This study aims...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend

Wong GL

The natural history of chronic hepatitis B (CHB) is complex and may run through different immune phases that may overlap. In particulars, the immune-tolerant phase is the most interesting and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience

Kim HJ, Cho YK, Jeon WK, Kim BI

BACKGROUND/AIMS: Clinical characteristics of patients with chronic hepatitis B (CHB) who developed genotypic resistance to entecavir (ETV) were compared to those without resistance. METHODS: Two hundred fifty eight CHB patients who...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B

Wi CI, Kim WR, Gross JB, Stadheim L, Poterucha

BACKGROUND/AIMS: Despite the potent suppression of the hepatitis B virus with modern antiviral agents, only a minority of HBeAg-positive patients achieve hepatitis B e antigen seroconversion. We aimed to explore...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The effect of low dose corticosteroid therapy on viral reactivation in patients with chronic hepatitis B virus infection

Lee HI, Gwak GY, Park MK, Suh HJ, Lee JH, Koh KC, Paik SW, Yoo BC

  • KMID: 2256193
  • Korean J Med.
  • 2008 Jun;74(6):619-623.
BACKGROUND/AIMS: We investigated the effect of low dose corticosteroid therapy on HBV reactivation in patients with chronic HBV infection. METHODS: From August 1998 to March 2007, the HBsAg-positive patients who received...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Lamivudine Therapy for Korean Children with Chronic Hepatitis B

Koh H, Baek SY, Chung KS

PURPOSE: Lamivudine is known to be very effective in suppressing hepatitis B virus replication and virus induced necroinflammation. The aim of this study was to evaluate lamivudine therapy efficacy,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Change of HBV DNA Level as a Predictor of HBeAg Loss after Lamivudine Treatment

Jung JK, Lee CH, Kim EY, Jung JT, Choi JH, Han JM, Jin MI, Cho JY, Kim BS, Shin IH

BACKGROUND AND AIMS: Lamivudine is an effective, safe therapeutic agent for the treatment of chronic hepatitis B. The aim of this study was to investigate whether early suppression of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term Outcome after Prophylactic Lamivudine Treatment on Hepatitis B Virus Reactivation in Non-Hodgkin's Lymphoma

Kim JS, Hahn JS, Park SY, Kim YR, Park IH, Lee CK, Cheong JW, Lee ST, Min YH

Hepatitis B virus (HBV) reactivation is the frequent complication after cytotoxic chemotherapy in HBsAg-positive non-Hodgkin's lymphoma (NHL) patients. Pre-chemotherapy viral load may be a risk factor and HBeAg-positive status is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
HBV-specific CD8+ T cells for Sustained HBeAg Seroconversion after Lamivudine Therapy

Lee CK, Han KH, Suh JH, Cho YS, Won SY, Chon CY, Moon YM, Park IS

  • KMID: 760578
  • Korean J Hepatol.
  • 2005 Mar;11(1):34-42.
BACKGROUND/AIMS: Viral suppression of the hepatitis B virus (HBV) can be induced by lamivudine, but the relapse seen in many patients after cessation of lamivudine therapy is troublesome. We...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Analysis of Clinical Features and Hepatitis B Virus DNA Level in the Concomitant Cases of Hepatitis B Surface Antigen and Antibody

Jeon BR, Park R, Shin JW, Choi TY, Shin HB, Lee YK, Choi YJ, Kim HJ, Ahn JY

  • KMID: 1892723
  • Korean J Clin Microbiol.
  • 2004 Sep;7(2):105-110.
BACKGROUND: After an infection with HBV, HBsAg is the first virologic marker detectable in the serum. If anti-HBs against 'a'determinant of HBsAg appears, HBsAg will disappear and the patients will...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Relevancy between Liver Injury, Serum HBV-DNA, and Intrahepatic HBcAg in Young Male Chronic HBV Carriers

Kim TH, Kim YS, Yeom JJ, Cho EY, Kim HS, Kim HC, Park DS, Cho JH, Yoon GJ, Moon HB

  • KMID: 1113322
  • Korean J Gastroenterol.
  • 2004 Aug;44(2):84-92.
BACKGROUND/AIMS: Although the viral load is correlated with HBcAg, liver injury was not correlated to viral load in HBeAg positive patient. We aimed to study the inter-relationship of clinical...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Etiology and Clinical Consequence of Spontaneous Acute Exacerbation of Chronic Hepatitis B

Chae MJ, Kim BH, Jeong KH, Kim NH, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R

  • KMID: 760537
  • Korean J Hepatol.
  • 2004 Jun;10(2):99-107.
BACKGROUND/AIMS: Acute exacerbation (AE) of chronic hepatitis B (CHB) can occur spontaneously, and may be followed by HBeAg clearance. HBeAg seroconversion often coincides with the normalization of liver biochemical...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pretreatment ALT Level and Histologic Activity as Predictors of HBeAg Loss in Lamivudine Treatment for Chronic Hepatitis B

Kweon YO, Kang KH

  • KMID: 760529
  • Korean J Hepatol.
  • 2004 Mar;10(1):31-41.
BACKGROUND/AIMS: Lamivudine is a potent inhibitor of hepatitis B virus replication, but an increased incidence of YMDD mutation may be associated with its long term use. Thus, the decision...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Predictive Factors and Clinical Outcome of Viral Breakthrough during Lamivudine Treatment for Chronic Hepatitis B Infection

Park NH, Shin JW, Park JH, Bang SJ, Kim DH, Joo KR, Kim DH

  • KMID: 1085302
  • Korean J Hepatol.
  • 2003 Dec;9(4):293-303.
BACKGROUND/AIMS: Long-term treatment with lamivudine causes breakthrough, but the clinical course after lamivudine breakthrough is not well known. The aims of this study were to evaluate the clinical course...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Serum ALT and HBV DNA Levels in Patients with HBeAg-Negative Chronic Hepatitis B

Kim KH, Na IH, Cha JM, Cho YK, Park SY, Kim HP, Song CS, Heo J, Cho M

  • KMID: 1085301
  • Korean J Hepatol.
  • 2003 Dec;9(4):284-292.
BACKGROUND/AIMS: HBeAg-negative chronic hepatitis B (CHB) has a poor long-term prognosis. Since no precise clinically relevant HBV thresholds are known in HBeAg-negative CHB, the decision to treat is difficult....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Predictive Factors and Efficacy of Lamivudine Treatment in Chronic Hepatitis B Infection

Park NH, Shin JW, Park JH, Bang SJ, Kim DH, Joo KR, Kim DH

  • KMID: 772561
  • Korean J Gastroenterol.
  • 2003 Oct;42(4):303-312.
BACKGROUND/AIMS: Lamivudine, an oral nucleoside analogue, effectively suppresses hepatitis B virus (HBV) replications and improves liver enzymes as well as liver histology. The aim of this study was to evaluate...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical and Histologic Evaluation on HBeAg Positive and Negative Chronic Hepatitis B in Young Adults

Jung PJ, Park CH, Noh DY, Joo YE, Choi SK, Rew JS, Kim SJ

  • KMID: 2274933
  • Chonnam Med J.
  • 2003 Jun;39(2):73-78.
It has recently been reported was active viral replication and severe liver damage may persist in HBeAg negative chronic hepatitis B. This study was aimed to compare clinical, biochemical, and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of Lamivudine in Patients with Hepatitis B e Antigen-Negative Chronic Liver Diseases

Jeong ID, Park NH, Kim BC, Park JH, Seo KW, Kim DH, Joo KR, Kim DH

  • KMID: 863140
  • Korean J Hepatol.
  • 2003 Jun;9(2):69-78.
BACKGROUND/AIMS: Lamivudine therapy is effective in inhibiting HBV replications in patients with HBeAg-negative chronic liver disease. However, the sustained response rate appears to be particularly poor, because the vast...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Serum Hepatitis B Virus DNA Quantitative Analysis Using Polymerase Chain Reaction in Patients with Chronic Hepatits B Virus Infection

Oh SH, Kim HH, Heo J, Cho M, Chang CL, Lee EY, Son HC

  • KMID: 1866519
  • Korean J Lab Med.
  • 2003 Feb;23(1):39-44.
BACKGROUND: The treatment using more potent antiviral agents for the hepatitis B virus (HBV) infection has been performed widely and a highly sensitive quantification method using the polymerase chain reaction...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Viral Breakthrough in HBeAg-Negative Chronic Hepatitis B Patients Receiving Lamivudine Therapy

Chang YJ, Yim JY, Cho NY, Choi CW, Baek SJ, Ahn SH, Choi DW, Kwon YD, Kim SS, Kwon OS, Kim JH, Yeon JE, Song JW, Byun KS, Lee CH

  • KMID: 863115
  • Korean J Hepatol.
  • 2002 Dec;8(4):397-404.
BACKGROUND/AIMS: Long-term efficacy and the rate of viral breakthrough in patients with HBeAg- negative chronic hepatitis B receiving lamivudine therapy is uncertain. This study was conducted to determine the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr